Stock listing

Biolinerx Ltd.

Selected listing: YP2 · SWB · EUR · DE

Biolinerx Ltd. (Stuttgart:YP2), Health Technology. Latest release Sep 10, 2026: BioLineRx and Hemispherian AS to Present Encouraging GLIX1 Preclinical…

YP2:SWBEURDEUpdated October 2, 2026

Ticker: Stuttgart:YP2
Asset type: Stock
Sector: Health Technology
Industry: Pharmaceuticals: Major
Exchange: Stuttgart
Currency: EUR

Latest news from Biolinerx Ltd.

BioLineRx and Hemispherian AS to Present Encouraging GLIX1 Preclinical Efficacy Data and its Phase 1/2a Trial Design at the 21st Meeting of the European Association of Neuro-Oncology (EANO 2026)

September 10, 2026

BioLineRx Reports First Quarter 2026 Financial Results and Provides Corporate Update

May 27, 2026

BioLineRx to Report First Quarter 2026 Results on May 27, 2026

May 20, 2026

BioLineRx and Hemispherian Announce First Patient Dosed in Phase 1/2a Study of GLIX1 for the Treatment of Glioblastoma (GBM)

April 28, 2026

Hemispherian Initiates Phase 1/2a Clinical Trial of GLIX1 in Glioblastoma

April 8, 2026

All Biolinerx Ltd. news →

Events

Replays

BioLineRx Ltd. (BLRX) Q2 2026 Earnings Call
Mon, Aug 31, 2026 · 08:30 AM ET
Watch
BioLineRx Ltd. (BLRX) Q1 2026 Earnings Call
Wed, May 27, 2026 · 08:30 AM ET
Watch
BioLineRx Ltd. (BLRX) Q4 2025 Earnings Call
Mon, Mar 23, 2026 · 08:30 AM ET
Watch

Research Biolinerx Ltd.

Biolinerx Ltd. company profile

View the public company page for Biolinerx Ltd. on 6ix.

Biolinerx Ltd. news

Read company news and market updates connected to Biolinerx Ltd..

Biolinerx Ltd. investor events

Find investor webinars, events, and replay context for Biolinerx Ltd..